个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：

收录情况： ◇ 统计源期刊 ◇ 卓越：梯队期刊

作者：
Feng Huijing[1] * ; Xia Yang[2] * ; Wang Wenxian[3] * ; Xu Chunwei[4,5] * ; Wang Qian[6] * ; Song Zhengbo[3] ; Li Ziming[7] ; Yu Jinpu[8] ; Zhong Wenzhao[9] ; Wang Zhijie[10] ; Zhang Yongchang[11] ; Liu Jingjing[12] ; Zhang Shirong[13] ; Cai Xiuyu[14] ; Liu Anwen[15] ; Li Wen[2] ; Zhan Ping[5] ; Liu Hongbing[5] ; Lyu Tangfeng[5] ; Miao Liyun[16] ; Min Lingfeng[17] ; Lin Gen[18] ; Huang Long[15] ; Yuan Jingping[19] ; Jiang Zhansheng[20] ; Pu Xingxiang[21] ; Rao Chuangzhou[22] ; Lyu Dongqing[23] ; Yu Zongyang[24] ; Li Xiaoyan[25] ; Tang Chuanhao[26] ; Zhou Chengzhi[27] ; Mei Qi[1] ; Guo Hui[28] ; Chu Qian[29] ; Meng Rui[30] ; Liu Xuewen[31] ; Wu Jingxun[32] ; Zhou Jin[33] ; Zhu Zhengfei[34] ; Pan Weiwei[35] ; Pang Fei[36] ; Hu Meizhen[36] ; Wang Kai[36] ; Wu Fan[37] ; Xu Bingwei[38] ; Xu Ling[39] ; Wang Liping[40] ; Zhu Youcai[41] ; Li Jisheng[42] ; Xie Yanru[43] ; Lin Xinqing[27] ; Cai Jing[15] ; Wang Lin[44] ; Du Yingying[45] ; Yao Wang[46] ; Shi Xuefei[47] ; Niu Xiaomin[7] ; Yuan Dongmei[5] ; Yao Yanwen[5] ; Kang Jing[9] ; Zhang Jiatao[9] ; Zhang Chao[9] ; Gao Wenbin[48] ; Huang Jianhui[43] ; Zhang Yinbin[49] ; Sun Pingli[50] ; Wang Hong[51] ; Ye Mingxiang[5] ; Wang Dong[5] ; Wang Zhaofeng[5] ; Hao Yue[3] ; Wang Zheng[52] ; Wan Bing[53] ; Lyu Donglai[54] ; Jiao Xiaodong[55] ; Shi Lin[56] ; Lan Gang[41] ; Yang Shengjie[57] ; Shang Yanhong[58] ; Wang Yina[59] ; Li Bihui[60] ; Jin Gang[61] ; Zheng Kang[62] ; Ma Jun[63] ; Li Wenfeng[64] ; Zhang Zhang[65] ; Li Zhongwu[66] ; Li Yuan[67] ; Liu Zhefeng[51] ; Ma Xuelei[68] ; Yang Nong[11] ; Wu Lin[21] ; Wang Qiming[69] ; Wang Guansong[70] ; Hong Zhuan[71] ; Wang Jiandong[72] ; Fang Meiyu[3] ; Fang Yong[73] ; Zhu Xixu[52] ; Shen Yi[74] ; Wang Ke[75,76] ; Ren Xiubao[77] ; Zhang Yiping[3] ; Ma Shenglin[78] ; Zhang Junping[1] ; Song Yong[5] ; Fang Wenfeng[79] ; Lu Yuanzhi[80] ;
机构： [1]Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China. [2]Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Cancer Center, Zhejiang University, Hangzhou 310009, China. [3]Department of Chemotherapy, Chinese Academy of Sciences University Cancer Hospital (Zhejiang Cancer Hospital), Hangzhou 310022, China. [4]Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China. [5]Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. [6]Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing 210029, China. [7]Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China. [8]Department of Cancer Molecular Diagnostics Core, Tianjin Medical University Cancer Institute Hospital, Tianjin 300060, China. [9]Guangdong Lung Cancer Institute, Guangdong Provincial Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, Guangzhou 510080, China. [10]State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China. [11]Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. [12]Department of Thoracic Cancer, Jilin Cancer Hospital, Changchun 130012, China. [13]Translational Medicine Research Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China. [14]Department of VIP Inpatient, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. [15]Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, China. [16]Department of Respiratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China. [17]Department of Respiratory Medicine, Clinical Medical School of Yangzhou University, Subei People's Hospital of Jiangsu Province, Yangzhou 225001, China. [18]Department of Medical Oncology, Fujian Medical University Cancer Hospital Fujian Cancer Hospital, Fuzhou 350014, China. [19]Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China. [20]Department of Integrative Oncology, Tianjin Medical University Cancer Institute Hospital, Tianjin 300060, China. [21]Department of Medical Oncology, Lung Cancer and Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China. [22]Department of Radiotherapy and Chemotherapy, Hwamei Hospital, University of Chinese Academy of Sciences, Ningbo 315010, China. [23]Department of Pulmonary Medicine, Taizhou Hospital of Wenzhou Medical University, Taizhou 317000, China. [24]Department of Respiratory Medicine, the 900th Hospital of the Joint Logistics Team (the Former Fuzhou General Hospital), Fujian Medical University, Fuzhou 350025, China. [25]Department of Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100700, China. [26]Department of Medical Oncology, Peking University International Hospital, Beijing 102206, China. [27]State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510300, China. [28]Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China. [29]Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. [30]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. [31]Department of Oncology, the Third Xiangya Hospital, Central South University, Changsha 410013, China. [32]Department of Medical Oncology, the First Affiliated Hospital of Medicine, Xiamen University, Xiamen 361003, China. [33]Department of Medical Oncology, Sichuan Cancer Hospital Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610041, China. [34]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [35]Department of Cell Biology, College of Medicine, Jiaxing University, Jiaxing 314001, China. [36]Shanghai OrigiMed Co, Ltd, Shanghai 201114, China. [37]Menarini Silicon Biosystems SpA, Shanghai 200333, China. [38]Department of Biotherapy, Cancer Institute, First Affiliated Hospital of China Medical University, Shenyang 110001, China. [39]Department of Interventional Pulmonary Diseases, Anhui Chest Hospital, Hefei 230011, China. [40]Department of Oncology, Baotou Cancer Hospital, Baotou 014000, China. [41]Department of Thoracic Disease Diagnosis and Treatment Center, Zhejiang Rongjun Hospital, The Third Affiliated Hospital of Jiaxing University, Jiaxing 314000, China. [42]Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250012, China. [43]Department of Oncology, Lishui Municipal Central Hospital, Lishui 323000, China. [44]Department of Pathology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China. [45]Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China. [46]Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510060, China. [47]Department of Respiratory Medicine, Huzhou Hospital, Zhejiang University School of Medicine, Huzhou 313000, China. [48]Department of Oncology, The Third Affiliated Hospital of Shenzhen University, Shenzhen 518001, China. [49]Department of Oncology, the Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710004, China. [50]Department of Pathology, The Second Hospital of Jilin University, Changchun 130041, China. [51]Senior Department of Oncology, The 5th Medical Center of Chinese PLA General Hospital, Beijing 100071, China. [52]Department of Radiation Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. [53]Department of Respiratory Medicine, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing 210002, China. [54]Department of Clinical Oncology, The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei 230031, China. [55]Department of Medical Oncology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai 200070, China. [56]Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. [57]Department of Thoracic Surgery, Chuxiong Yi Autonomous Prefecture People's Hospital, Chuxiong 675000, China. [58]Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China. [59]Department of Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China. [60]Department of Oncology, The Second Affiliated Hospital of Guilin Medical University, Guilin 541199, China. [61]Department of Oncology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, China. [62]Department of Thoracic Surgery, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030013, China. [63]Department of Thoracic Surgery, Shanxi Provincial People's Hospital/The Fifth Hospital of Shanxi Medical University/The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China. [64]Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical College, Wenzhou 325000, China. [65]International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Development, School of Pharmacy, Jinan University, Guangzhou 510632, China. [66]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital Institute, Beijing 100142, China. [67]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China. [68]Department of Biotherapy, State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China. [69]Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China. [70]Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China. [71]Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing Medical University Affiliated Cancer Hospital, Nanjing 210029, China. [72]Department of Pathology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. [73]Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, China. [74]Department of Thoracic Surgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China. [75]National Health Commission (NHC) Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China. [76]Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing 210000, China. [77]Department of Immunology, Tianjin Medical University Cancer Institute Hospital, Tianjin 300060, China. [78]Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou Cancer Hospital, Cancer Center, Zhejiang University School of Medicine, Hangzhou 310006, China. [79]Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. [80]Department of Clinical Pathology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China.
出处：
DOI： 10.20892/j.issn.2095-3941.2024.0503
ISSN：

关键词： Mesenchymal-epithelial transition factor MET exon 14 skipping mutation MET amplification non-small cell lung cancer precision medicine targeted therapy tyrosine kinase

摘要：
Alterations in the mesenchymal-epithelial transition factor (MET) gene are critical drivers of non-small cell lung cancer (NSCLC). In recent years advances in precision therapies targeting MET alterations have significantly expanded treatment options for NSCLC patients. These alterations include MET exon 14 skipping mutations (MET exon 14 skipping), MET gene amplifications, MET point mutations (primarily kinase domain mutations), and MET protein overexpression. Accurate identification of these alterations and appropriate selection of patient populations and targeted therapies are essential for improving clinical outcomes. The East China Lung Cancer Group, Youth Committee (ECLUNG YOUNG, Yangtze River Delta Lung Cancer Cooperation Group) has synthesized insights from China's innovative drug development landscape and clinical practice to formulate an expert consensus on the diagnosis and treatment of NSCLC patients with MET alterations. This consensus addresses key areas, such as optimal testing timing, testing methods, testing strategies, quality control measures, and treatment approaches. By offering standardized recommendations, this guidance aims to streamline diagnostic and therapeutic processes and enhance clinical decision-making for NSCLC with MET alterations.Copyright © 2025 The Authors.

语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2026]版：
无
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 医学：研究与实验 2 区 肿瘤学
第一作者：
第一作者机构： [1]Department of Thoracic Oncology, Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Taiyuan 030032, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Feng Huijing,Xia Yang,Wang Wenxian,et al.Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration[J].Cancer Biology & Medicine.2025,22(3):237-65.doi:10.20892/j.issn.2095-3941.2024.0503.
APA：
Feng Huijing,Xia Yang,Wang Wenxian,Xu Chunwei,Wang Qian...&Lu Yuanzhi.(2025).Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.Cancer Biology & Medicine,22,(3)
MLA：
Feng Huijing,et al."Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration".Cancer Biology & Medicine 22..3(2025):237-65

相关文献

[1]Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer [2]Delayed cardiotoxicity following osimertinib therapy in non-small cell lung cancer: a unique case report [3]Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer [4]靶向药物和全脑放疗治疗非小细胞肺癌脑转移的研究现状 [5]Transcription factor YY1 mediates epithelial-mesenchymal transition through the TGFβ signaling pathway in bladder cancer. [6]Transformation from non-small cell lung cancer to small cell lung cancer: A report of clinicopathological characteristics and prognoses. [7]Curcumin inhibits cell proliferation and migration in NSCLC through a synergistic effect on the TLR4/MyD88 and EGFR pathways. [8]阿帕替尼治疗晚期非小细胞肺癌1例并文献复习 [9]miR-374a-5p inhibits non-small cell lung cancer cell proliferation and migration via targeting NCK1 [10]盐酸埃克替尼对人t淋巴细胞增殖的影响

资源点击量：15100 今日访问量：4 总访问量：960 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持：重庆聚合科技有限公司 地址：保定市莲池区裕华东路212号